Key Highlights
- Sarah Boyce brings over 25 years of life sciences industry experience.
- Focus on advancing ulviprubart in Phase 3 MUSCLE trial for inclusion body myositis.
- Ms. Boyce’s extensive background in global product development and commercialization.
- Previous leadership roles at Avidity Biosciences, Akcea Therapeutics, and more.
- Named a Top 25 Biotech CEO and one of the Fiercest Women in Life Sciences.
Source: Business Wire
Notable Quotes
- “I look forward to collaborating with the management team, providing guidance and sharing my expertise as the company progresses towards potential regulatory approval and readiness for potential commercialization.” — Sarah Boyce, President and CEO at Avidity Biosciences
- “We are excited to welcome Sarah as a member of the Board and her experience will be instrumental as we focus on advancing ulviprubart in the ongoing Phase 3 MUSCLE trial for the treatment of inclusion body myositis.” — Mark Pruzanski, M.D., Chairman of the Board of Directors at Abcuro
SoHC's Take
The appointment of Sarah Boyce to Abcuro’s Board of Directors is a strategic move that significantly strengthens the company’s leadership. With over 25 years of experience in the life sciences industry and a proven track record in global product development and commercialization, Ms. Boyce is poised to provide invaluable guidance as Abcuro advances its clinical programs, particularly the Phase 3 MUSCLE trial for ulviprubart. Her expertise in navigating regulatory approvals and market readiness will be crucial as Abcuro moves closer to bringing innovative treatments for autoimmune diseases and cancer to patients.
